[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

633A.O2.6 633. Myelodysplastic Syndromes: Advances in the Therapy of MDS

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 2:45 PM-4:15 PM
Room 6CF (San Diego Convention Center)
Thomas Prebet, MD, PhD, Institut Paoli Calmettes and Steven D. Gore, MD, Sidney Kimmel Cancer Center, The Johns Hopkins University

Prebet: celgene: Research Funding. Gore: Celgene: Consultancy, Equity Ownership, Research Funding.
2:45 PM
Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Mikkael A. Sekeres, MD, MS1, Rami S. Komrokji, MD2, Jeffrey E. Lancet, MD2, Ramon V. Tiu, MD3, Anjali S. Advani, MD4, Manual Afable3*, Ricki Englehaupt3*, Joyce Juersivich3*, David Cuthbertson, M.S.5*, Jennifer Paleveda2*, Ronald Paquette, MD, PhD6*, April Smith3*, Lori Strozniak3*, Alan F. List, MD7 and Jaroslaw P. Maciejewski, MD, PhD3

1Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
3Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
4Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Pediatrics Epidemiology Center, University of South Florida, Tampa, FL
6UCLA Medical Hematology & Oncology, Los Angeles, CA
7Moffitt Cancer Center, Tampa, FL

3:00 PM
Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities

Guillermo Garcia-Manero1, Elihu H Estey, MD2, Elias Jabbour, MD1, Gautam Borthakur1, Tapan Kadia1, Kiran Naqvi, MD3*, Ross L Levine, MD4, Zeev Estrov1, Alfonso Quintas-Cardama, MD1, Marina Konopleva, M.D., Ph.D.5, Stefan Faderl, MD1, Maria Tanaka, MD6*, Hui Yang1*, Farhad Ravandi, MD1, William G. Wierda, MD, PhD1, Jorge E. Cortes, MD1, Patricia Ann Boone1* and Hagop M. Kantarjian1

1Leukemia, MD Anderson Cancer Center, Houston, TX
2Hematology/Oncology, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
3Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
5mdacc, Houston, TX
6Hematology/Oncology, Baylor College of Medicine, Houston, TX

3:15 PM
Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)Clinically Relevant Abstract

Thorsten Braun1*, Emmanuel Raffoux, MD, PhD2*, Thomas Prebet, MD, PhD3, Sabine Brechignac1*, Aspasia Stamatoullas4*, Francois Dreyfus5*, Zehaira Hebibi6*, Lionel Ades1, Norbert Vey, MD3*, Hervé Dombret2*, Pierre Fenaux, MD, PhD1 and Claude Gardin1*

1Hematology Department, Avicenne Hospital APHP University Paris XIII, Bobigny, France
2Hematology Department, Saint-Louis Hospital APHP University Paris VII, Paris, France
3Hematology Department, Institut Paoli Calmettes, Marseille, France
4Hematology Department, Centre Henri Becquerel, Rouen, France
5Hematology , APHP, Cochin Hospital, University Paris Descartes, Paris, France
6Groupe Francophone des Myelodysplasies (GFM), Bobigny, France

3:30 PM
RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in Myelodysplastic Syndromes

Rajasekhar NVS Suragani1, Aaron Mulivor2*, R. Scott Pearsall1* and Ravindra Kumar3*

1Preclinical Pharmacology, Acceleron Pharma, Cambridge, MA
2Acceleron Pharma, Cambridge, MA
3Biology, Acceleron Pharma, Cambridge, MA

3:45 PM
High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload : An Italian Multicenter Retrospective StudyClinically Relevant Abstract

Daniela Cilloni, MD, PhD1*, Emanuela Messa2*, Lucia Biale, MD3*, Margherita Bonferroni, MD4*, Flavia Salvi, MD5*, Monia Lunghi, M.D.6*, Bernardino Allione7*, Dario Ferrero8*, Roberto Freilone, MD9*, Alessandro Levis, MD10 and Giuseppe Saglio11

1Dept. of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
2MDS Piedmont Registry, Hematology-AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy
3Blood bank , Ospedale Molinette, Turin, Italy
4Hematology Department, Ospedale S.Croce e Carle, Cuneo, Italy
5Hematology, AO SS Antonio e Biagio e C. Arrigo, Alessandria , Italy
6Division of Hematology, Department of Clinical and Experimental Medicine & IRCAD, Amedeo Avogadro University Hospital, Novara, Novara, Italy
7Ematologia, AO San Giovanni Battista, Torino, Italy
8AO San Giovanni Battista, University of Turin, Turin, Italy
9Ematologia, Ospedale R.S.A, Ciriè, Italy
10Hematology, AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy
11University of Turin, Turin, Italy

4:00 PM
Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Garrett Rhyasen, BSc1*, Lyndsey Bolanos, BSc1*, Jing Fang, MD/PhD1*, Carmen Rigolino, BSc2*, Agostino Cortelezzi, MD3*, Esther Natalie Oliva, MD4, Mariella Cuzzola, MD2* and Daniel T Starczynowski, PhD1,5

1Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
2Bone Marrow Transplant Unit, Azienda Ospedaliera , Reggio Calabria, Italy
3Hematology, IRCCS Fondazione Ca’ Granda and University, Milan, Italy
4Hematology Unit, Azienda Ospedaliera B-M-M, Reggio Calabria, Italy
5Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH

*signifies non-member of ASH